| Literature DB >> 33737227 |
Raul Macias Gil1, Francine Touzard-Romo2, Martha C Sanchez2, Aakriti Pandita3, Markos Kalligeros2, Evangelia K Mylona2, Fadi Shehadeh2, Eleftherios Mylonakis4.
Abstract
OBJECTIVE: Explore potential racial/ethnic differences, describe general clinical characteristic, and severe outcomes (intensive care unit [ICU] admission, mechanical ventilation [intubation], and death) between Hispanic/Latinx (hereafter: Hispanics or Latinx community) and non-Hispanic patients hospitalized with COVID-19.Entities:
Keywords: Covid-19; Health disparity; Hospitalization, Hispanic; Latinx; Sars-cov-2
Year: 2021 PMID: 33737227 PMCID: PMC7962584 DOI: 10.1016/j.annepidem.2021.03.003
Source DB: PubMed Journal: Ann Epidemiol ISSN: 1047-2797 Impact factor: 3.797
Clinical and demographic characteristics of Hispanics/Latinx, non-Hispanic African Americans, and non-Hispanic White patients with COVID-19 requiring hospitalization.
| Total | HL | NHAA | NHW | ||
|---|---|---|---|---|---|
| 61 | 53.5 | 63 | 67 | <.001 | |
| Age IQR | (49.00–74.00) | (44.00–66.00) | (54.00–70.00) | (56.00–77.00) | |
| .31 | |||||
| Female | 144 (44.2%) | 49 (38.9%) | 26 (47.3%) | 69 (47.6%) | |
| Male | 182 (55.8%) | 77 (61.1%) | 29 (52.7%) | 76 (52.4%) | |
| <.001 | |||||
| Commercial/HMO/PPO | 64 (19.6%) | 18 (14.3%) | 14 (25.5%) | 32 (22.1%) | |
| Medicaid | 93 (28.5%) | 59 (46.8%) | 14 (25.5%) | 20 (13.8%) | |
| Medicare | 161 (49.4%) | 45 (35.7%) | 25 (45.5%) | 91 (62.8%) | |
| Self-pay | 8 (2.5%) | 4 (3.2%) | 2 (3.6%) | 2 (1.4%) | |
| Comorbidities | |||||
| Cardiac/Pulmonary | |||||
| Congestive heart failure | 30 (9.2%) | 7 (5.6%) | 5 (9.1%) | 18 (12.4%) | .15 |
| Cardiac arrhythmias | 63 (19.3%) | 7 (5.6%) | 10 (18.2%) | 46 (31.7%) | <.001 |
| Valvular disease | 15 (4.6%) | 2 (1.6%) | 1 (1.8%) | 12 (8.3%) | .02 |
| Peripheral vascular disorders | 20 (6.1%) | 5 (4.0%) | 3 (5.5%) | 12 (8.3%) | .33 |
| Hypertension | 148 (45.4%) | 47 (37.3%) | 30 (54.5%) | 71 (49.0%) | .05 |
| Pulmonary circulation disorders | 12 (3.7%) | 4 (3.2%) | 1 (1.8%) | 7 (4.8%) | .56 |
| Chronic pulmonary disease | 48 (14.7%) | 18 (14.3%) | 7 (12.7%) | 23 (15.9%) | .84 |
| Obesity | 130 (39.9%) | 44 (34.9%) | 24 (43.6%) | 62 (42.8%) | .35 |
| Diabetes | 109 (33.4%) | 45 (35.7%) | 21 (38.2%) | 43 (29.7%) | .41 |
| Hypothyroidism | 22 (6.7%) | 4 (3.2%) | 1 (1.8%) | 17 (11.7%) | .006 |
| Renal failure | 35 (10.7%) | 3 (2.4%) | 13 (23.6%) | 19 (13.1%) | <.01 |
| Liver disease | 11 (3.4%) | 5 (4.0%) | 3 (5.5%) | 3 (2.1%) | .44 |
| Lymphoma | 4 (1.2%) | 2 (1.6%) | 0 (0.0%) | 2 (1.4%) | .66 |
| Metastatic cancer | 3 (0.9%) | 1 (0.8%) | 1 (1.8%) | 1 (0.7%) | .74 |
| Solid tumor without metastasis | 20 (6.1%) | 5 (4.0%) | 4 (7.3%) | 11 (7.6%) | .43 |
| Coagulopathy | 21 (6.4%) | 13 (10.3%) | 2 (3.6%) | 6 (4.1%) | .08 |
| AIDS/HIV | 4 (1.2%) | 1 (0.8%) | 2 (3.6%) | 1 (0.7%) | .20 |
| Rheumatoid arthritis/collagen vascular disease | 6 (1.8%) | 2 (1.6%) | 1 (1.8%) | 3 (2.1%) | .96 |
| Alcohol abuse | 18 (5.5%) | 5 (4.0%) | 5 (9.1%) | 8 (5.5%) | .38 |
| Drug abuse | 17 (5.2%) | 2 (1.6%) | 3 (5.5%) | 12 (8.3%) | .05 |
| Psychoses | 14 (4.3%) | 4 (3.2%) | 6 (10.9%) | 4 (2.8%) | .03 |
| 45 (13.8%) | 13 (10.3%) | 5 (9.1%) | 27 (18.6%) | .08 | |
| .02 | |||||
| 79 (24.2%) | 44 (34.9%) | 9 (16.4%) | 26 (17.9%) | ||
| 72 (22.1%) | 26 (20.6%) | 11 (20.0%) | 35 (24.1%) | ||
| 50 (15.3%) | 14 (11.1%) | 12 (21.8%) | 24 (16.6%) | ||
| 125 (38.3%) | 42 (33.3%) | 23 (41.8%) | 60 (41.4%) | ||
| 104 (31.9%) | 34 (27.0%) | 20 (36.4%) | 50 (34.5%) | .31 | |
| 60 (18.4%) | 24 (19.0%) | 11 (20.0%) | 25 (17.2%) | .88 | |
| 57 (17.5%) | 16 (12.7%) | 9 (16.4%) | 32 (22.1%) | .12 | |
E-vW score = Weighted Elixhauser-van Walraven comorbidity score; HL = Hispanic/Latinx; NHAA = Non-Hispanic African American; NHW = Non-Hispanic White.
Continuous values: median (IQR); categorical values: N (%).
Mann-Whitney-Wilcoxon and chi-squared tests used to calculate p-values (≤.05 considered statistically significant).
Logistic regression analysis: association between race/ethnicity and outcomes in hospitalized patients with COVID-19.
| ICU | Intubation | Death | ||||
|---|---|---|---|---|---|---|
| OR [95% CI] | OR [95% CI] | OR [95% CI] | ||||
| HL | 0.94 [0.53–1.67] | .84 | 1.32 [0.67–2.60] | .42 | 1 [0.46–2.16] | 1 |
| NHAA | 1.2 [0.61–2.36] | .59 | 1.27 [0.56–2.83] | .57 | 0.88 [0.35–2.19] | .79 |
| 1.01 [0.98–1.03] | .37 | 1 [0.98–1.03] | .74 | 1.06 [1.03–1.10] | <.001 | |
| Male | 1.42 [0.86–2.32] | .17 | 1.81 [0.99–3.29] | .05 | 0.94 [0.49–1.78] | .84 |
| Medicaid | 0.59 [0.27–1.26] | .18 | 0.62 [0.25–1.47] | .28 | 2.02 [0.48–8.39] | .33 |
| Medicare | 1.02 [0.49–2.12] | .95 | 0.87 [0.37–2.03] | .74 | 2.14 [0.56–8.07] | .26 |
| Self-pay | 0.75 [0.13–4.14] | .74 | 0.55 [0.06–4.95] | .59 | 3.38 [0.28–40.47] | .34 |
| 1.04 [1.00–1.07] | .04 | 1.02 [0.98–1.06] | .28 | 1.04 [0.99–1.08] | .06 | |
CI = confidence intervals; E-vW score = Weighted Elixhauser-van Walraven comorbidity score; HL = Hispanic/Latinx; NHAA = Non-Hispanic African American; OR = odds ratio.
Reference variables (not shown): for racial/ethnic group: non-Hispanic White; for healthcare coverage (coverage): Commercial/HMO/PPO.
Logistic regression.
P values ≤.05 considered statistically significant.
Logistic regression analysis: association between race/ethnicity and outcomes by age group (<65 and ≥65-year-old) in hospitalized patients with COVID-19
| Outcome: | ICU | Intubation | Death | |||
|---|---|---|---|---|---|---|
| Age subgroups (years) | <65 | ≥65 | <65 | ≥65 | <65 | ≥65 |
| OR [95% CI]; | OR [95% CI]; | OR [95% CI]; | OR [95% CI]; | OR [95% CI]; | OR [95% CI]; | |
| HL | 0.46 [0.20 - 1.04]; .06 | 2.66 [1.07 - 6.61]; .03 | 0.56 [0.21 - 1.48]; .24 | 3.66 [1.29 - 10.36]; .01 | 0.09 [0.01 - 0.83]; .03 | 1.55 [0.62 - 3.91]; .34 |
| HL unadjusted | 0.36 [0.17–0.74]; .01 | 2.08 [0.94–4.64]; .07 | 0.48 [0.20–1.14]; .10 | 3.73 [1.46–9.53]; .01 | 0.11 [0.01–0.88]; .04 | 1.28 [0.57–2.87]; .55 |
| NHAA adjusted | 0.99 [0.40 - 2.44]; .99 | 1.25 [0.44 - 3.54]; .67 | 1.17 [0.42 - 3.24]; .75 | 0.86 [0.19 - 3.77]; .84 | 0.71 [0.15 - 3.39]; .67 | 0.76 [0.25 - 2.31]; .63 |
| NHAA unadjusted | 0.99 [0.42–2.33]; .98 | 1.19 [0.44–3.22]; .731 | 1.19 [0.45–3.18]; .72 | 1.01 [0.25–4.05]; .99 | 0.91 [0.22–3.78]; .90 | 0.74 [0.26–2.11]; .57 |
| 1.02 [0.99 - 1.06]; .08 | 0.97 [0.93 - 1.02]; .37 | 1.02 [0.98 - 1.06]; .25 | 0.93 [0.87 - 1.00]; .05 | 1.03 [0.96 - 1.11]; .36 | 1.04 [0.99 −1.09]; .06 | |
| Male | 1.02 [0.99 - 1.06]; .08 | 1.08 [0.51 - 2.27]; .83 | 2.1 [0.91 - 5.25]; .07 | 1.37 [0.54 - 3.42]; .49 | 0.71 [0.18 - 2.76]; .62 | 0.99 [0.47 - 2.09]; .47 |
| Medicaid | 0.64 [0.27 - 1.50]; .31 | 5.96 [0.31 - 111.65]; .23 | 0.78 [0.30 - 2.06]; .62 | 3.31 [0.13 - 81.53]; .46 | 7.29 [0.78 - 67.79]; .08 | 2.03 [0.13 - 29.97]; .60 |
| Medicare | 1.15 [0.45 - 2.94]; .76 | 6.93 [0.73 - 65.04]; .09 | 0.93 [0.31 - 2.79]; .90 | 4.08 [0.41 - 40.24]; .22 | 4.2 [0.38 - 45.96]; .23 | 1.27 [0.20 - 1.82]; .79 |
| Self-pay | 0.61 [0.06 - 5.83]; .67 | 6.72 [0.18 - 238.57]; .29 | 1 - empty | 8.1 [0.20 −325.95]; .26 | 1 - empty | 4.03 [0.14 - 111.42]; .41 |
| 1.02 [0.97 - 1.07]; .33 | 1.04 [0.99 - 1.10]; .06 | 1.00 [0.95 - 1.06]; .75 | 1.03 [0.97 - 1.10]; .25 | 1.06 [0.99 - 1.15]; .79 | 1.01 [0.96 - 1.07]; .46 | |
CI = confidence intervals; E-vW score = Weighted Elixhauser-van Walraven comorbidity score
; HL = Hispanic/Latinx; NHAA = Non-Hispanic African American;
OR = odds ratio.
The words “adjusted” and “unadjusted” refer to the odd ratios for each variable.
Logistic regression.
Reference variables (not shown): for racial/ethnic group: non-Hispanic White; for healthcare coverage (coverage): Commercial/HMO/PPO.
P values ≤.05 considered statistically significant.